COMMUNIQUÉS West-GlobeNewswire

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
17/10/2025
- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and [...]
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
17/10/2025
Provides clarity on the aspects to incorporate Company to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, [...]
Fagron’s share buy-back program: Weekly update
17/10/2025
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 16 October 2025 through 17 October 2025, Fagron purchased [...]
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
17/10/2025
Acquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc [...]
Communiqué de presse : Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire
17/10/2025
Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire Recommandation fondée sur l’étude de phase 3 LUNA 3 démontrant une réponse plaquettaire [...]
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
17/10/2025
Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant improvements in [...]
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
17/10/2025
Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product [...]
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
17/10/2025
WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of [...]
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation
17/10/2025
Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National Priority Voucher Program [...]
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
17/10/2025
Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0. [...]
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025
17/10/2025
Highlights include clinical data from Phase 3 studies in Community Acquired Pneumonia (CABP) and microbiologic data from a Phase 2 study in nontuberculous mycobacterial pulmonary disease (NTM-PD) caused by Mycobacterium [...]
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
17/10/2025
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran At the closing of the [...]
SRx Health Solutions Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
17/10/2025
TAMPA, Fla., Oct. 17, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced it received a notice from the staff of NYSE American LLC (the “Exchange”) that the Company [...]
Zus Health Helps Value-Based Care Organizations Capture Accurate Risk with Intuitive, Evidence-Based Workflows
17/10/2025
BOSTON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Zus Health , the always-on data platform that unifies every patient record into a single, comprehensive view, today announced new capabilities for accurately capturing a patient [...]
Anthem Blue Cross and Blue Shield and Sauk Prairie Healthcare to Strengthen Health Outcomes in Wisconsin
17/10/2025
New multi-year agreement continues Anthem members’ access to high-quality, affordable care MADISON, Wisc., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Anthem Blue Cross and Blue Shield in Wisconsin (Anthem) and Sauk Prairie [...]
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
17/10/2025
6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response, observed in the [...]
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
17/10/2025
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a [...]
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
17/10/2025
LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, [...]
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
17/10/2025
After 5 years, Kisqali ® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival 1 Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and [...]

Pages